RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) on October 8 ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Day One Biopharmaceuticals (DAWN – Research ...

Many companies near the bottom of our list in previous years — such as Silk Road Medical and Axonics — have struck deals to be acquired by top 20 medtech companies. M&A also consolidated the revenue ...

This page features the latest news about the Axonics Modulation Technologies stock. Axonics stock hits 52-week high at $69.91 amid robust growth Axonics Modulation Technologies , Inc. (NASDAQ ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting ...

Axonics, Inc. (Nasdaq:AXNX) has reached a significant milestone with the Therapeutic Goods Administration's (TGA) recent approval to market its Axonics R20® rechargeable sacral neuromodulation (SNM) ...

Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral ...

Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20 ® rechargeable sacral ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20 ...